Hsd10 Mitochondrial Disease, also known as 2-methyl-3-hydroxybutyryl-coa dehydrogenase deficiency, is related to syndromic x-linked intellectual disability type 10 and 2-methylbutyryl-coa dehydrogenase deficiency, and has symptoms including muscle spasticity, seizures and agitation. An important gene associated with Hsd10 Mitochondrial Disease is HSD17B10 (Hydroxysteroid 17-Beta Dehydrogenase 10). The drugs Bortezomib and Rituximab have been mentioned in the context of this disorder. Affiliated tissues include heart and bone marrow, and related phenotypes are seizure and global developmental delay